Transgene

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 608
Lid geworden op: 06 Sep 2018 20:48
waarderingen: 224
Contact:

Re: Transgene

Berichtdoor Naz-T » 02 Mei 2019 20:10

Jelle R schreef:Is dit dan de uitbraak waar we al zo lang op wachten? Technisch gezien is dit een zeer belangrijke uitbraak.

Oei, ik ben vandaag met lichte winst uitgestapt. Morgen dan best terug op de trein springen zeker? :oops:


Beleggen met zeer lage tarieven?
Goedkoopste in België, scherp in Nederland



powered by Surfing Waves

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 256
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 103
Contact:

Re: Transgene

Berichtdoor And its gone! » 13 Mei 2019 21:21

BRIEF-Transgene Cash Position At End-Q1 9.1 Million Euros
17:51 (13/05) - Bron: Reuters
May 13 (Reuters) - TRANSGENE SA TRNG.PA :
* EUR 9.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH
31,
2019
* KEY CLINICAL TRIALS CONFIRMED TO READOUT IN H2 2019
* €20 MILLION REVOLVING CREDIT FACILITY SECURED WITH NATIXIS
* TRANSGENE EXPECTS ITS CASH BURN FOR 2019 TO BE BETWEEN EUR
15
MILLION AND EUR 20 MILLION
* Q1 OPERATING REVENUE EUR 1.9 MILLION VERSUS EUR 1.8
MILLION YEAR
AGO
* HAS EXTENDED ITS FINANCIAL VISIBILITY TO Q4 2020
* CONFIRMS THAT IT EXPECTS READOUTS FROM ITS KEY CLINICAL
TRIALS
IN SECOND HALF OF 2019

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))


Financial visibility extended to Q4 2020, including $10 million revenue from
collaboration with AstraZeneca to be received in Q2 2019
✓ €9.1 Million in Cash and Cash Equivalents as of March 31, 2019
✓ €20 million revolving credit facility secured with Natixis
✓ Key clinical trials confirmed to readout in H2 2019
Strasbourg, France, May 13, 2019, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that
designs and develops virus-based immunotherapies against cancers and infectious diseases to transform the
fight against solid tumors and infectious diseases, today announces its business update for the quarter ending
March 31, 2019.
Operating revenue:
The following table summarizes the first quarter operating revenue for 2019 compared to the same period in
2018:
Q1
In millions of euros 2019 2018
Revenue from collaborative and licensing agreements 0.4 0.2
Government financing for research expenditures 1.5 1.6
Operating revenue 1.9 1.8
During the first quarter of 2019, revenue from collaborative and licensing agreements was mainly composed of
research services and royalties.
As of March 31, 2019, government financing for research expenditures mainly consisted of 25% of the research
tax credit expected for 2019 (€1.5 million in the first quarter of 2019, compared to €1.6 million for the same
period in 2018).
Cash, cash equivalents, available-for-sale financial assets and other financial assets:
In the first quarter of 2019, Transgene’s cash burn was €7.8 million, compared to €5.8 million for the same period
in 2018. Cash, cash equivalents, available-for-sale financial assets and other financial assets stood at €9.1 million
as of March 31, 2019, compared to €16.9 million as of December 31, 2018. This cash position does not include
the €20 million credit facility available for the Company or the $10 million receivable from AstraZeneca.
Key achievements:
• Finance:
o Transgene secured a €20 million revolving credit facility with a 30-month term with Natixis.
Transgene will be able to draw on and repay the facility at its discretion. Transgene has used its
shares in the Chinese biotech company Tasly Biopharmaceuticals as collateral for this loan (press
Page 2 / 3
release distributed on March 18, 2019). As of May 13, 2019, the Company has not drawn down
on this facility.
• Invir.IO™:
o Transgene and AstraZeneca signed a collaborative research, option and exclusive license
agreement to co-develop five armed oncolytic vaccinia virus candidates deriving from the
Invir.IO™ platform.
Transgene is to receive $10 million in Q2 2019 and additional pre-clinical success milestones of
up to $3 million. Transgene is eligible to receive an option exercise payment on each candidate
in the event AstraZeneca exercises one or more of its license option, as well as development and
commercial milestones and royalties (press release distributed on May 2, 2019).
o Transgene and BioInvent extend their collaboration to develop additional multifunctional
oncolytic viruses encoding for antibodies capable of treating a broad range of solid tumors (press
release distributed on March 26, 2019).
• myvac™:
o Transgene announced that the NEOVIVA project, that is focused on Transgene’s individualized
immunotherapy platform myvac™, was selected by the “Investments for the Future” Program
(Programme d’Investissements d’Avenir) operated by Bpifrance. The NEOVIVA project will
receive €5.2 million over the five-year duration of the program from Bpifrance, of which
Transgene will receive €2.6 million (press release distributed on March 13, 2019).
• TG4050:
o Transgene announced its decision to initiate clinical developments of its lead myvac™
candidate, TG4050, and the finalization of its collaboration agreement with NEC (press release
distributed on March 5, 2019).
o Transgene received FDA IND clearance for TG4050 to commence clinical development in ovarian
cancer (press release distributed on May 13, 2019).
Outlook:
Transgene expects its cash burn for 2019 to be between €15 million and €20 million, based on its current
development plan and cash-in from the collaboration with AstraZeneca.
As a result of the financing agreement with Natixis and the signing of the collaboration with AstraZeneca,
Transgene has extended its financial visibility to Q4 2020.
Transgene confirms that it expects readouts from its key clinical trials in the second half of 2019.
- End -
Laatst gewijzigd door And its gone! op 13 Mei 2019 21:51, 1 keer totaal gewijzigd.
Gillepils liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 256
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 103
Contact:

Re: Transgene

Berichtdoor And its gone! » 13 Mei 2019 21:24

BRIEF-Transgene Receives FDA Clearance To Commence Clinical Development In Ovarian Cancer For TG4050
07:39 (13/05) - Bron: Reuters
May 13 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™
INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL
DEVELOPMENT IN OVARIAN CANCER
* TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™
INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL
DEVELOPMENT IN OVARIAN CANCER
* RECEIVED INVESTIGATIONAL NEW DRUG (IND) CLEARANCE FROM FDA
TO
PROCEED WITH A PHASE 1 CLINICAL TRIAL OF ITS LEAD MYVAC™
CANDIDATE TG4050
* PHASE 1 CLINICAL TRIAL WILL EVALUATE SAFETY AND
TOLERABILITY OF
TG4050 IN PATIENTS WITH OVARIAN, FALLOPIAN OR PERITONEAL SEROUS
CELL CARCINOMA
* STUDY, SPONSORED BY TRANSGENE, WILL BE CO-FINANCED BY
TRANSGENE
AND ITS PARTNER NEC
* PHASE 1 CLINICAL TRIAL, EXPECTED TO START IN H2 2019

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

Jelle R
Forum gebruiker
Forum gebruiker
Berichten: 175
Lid geworden op: 13 Sep 2018 11:31
waarderingen: 43
Contact:

Re: Transgene

Berichtdoor Jelle R » 14 Mei 2019 18:00

Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 256
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 103
Contact:

Re: Transgene

Berichtdoor And its gone! » 16 Mei 2019 17:55

Jelle R schreef:Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...


Ondertussen zitten we weer in de oude vertrouwde regio 2.8-3€ :lol:

Jelle R
Forum gebruiker
Forum gebruiker
Berichten: 175
Lid geworden op: 13 Sep 2018 11:31
waarderingen: 43
Contact:

Re: Transgene

Berichtdoor Jelle R » 16 Mei 2019 20:40

And its gone! schreef:
Jelle R schreef:Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...


Ondertussen zitten we weer in de oude vertrouwde regio 2.8-3€ :lol:


Ongelooflijk he? :roll: Dacht met het nieuws van AstraZeneca en de uitbraak dat we eindelijk een uptrend te pakken zouden hebben, maar weer wordt alles direct teruggedraaid. Er zijn toch geen partijen die baat hebben om de koers niet ver boven de 3€ te laten stijgen? Al sinds het najaar van 2015 dobberen we rond de 3€...

Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 515
Lid geworden op: 25 Dec 2013 21:48
waarderingen: 118
Contact:

Re: Transgene

Berichtdoor Stefkamielkafkajr » 17 Mei 2019 15:03

Jelle R schreef:
And its gone! schreef:
Jelle R schreef:Nieuws is niet goed bevallen precies. Meer dan 3% onderuit...


Ondertussen zitten we weer in de oude vertrouwde regio 2.8-3€ :lol:


Ongelooflijk he? :roll: Dacht met het nieuws van AstraZeneca en de uitbraak dat we eindelijk een uptrend te pakken zouden hebben, maar weer wordt alles direct teruggedraaid. Er zijn toch geen partijen die baat hebben om de koers niet ver boven de 3€ te laten stijgen? Al sinds het najaar van 2015 dobberen we rond de 3€...

ik vrees eerder dat er een uitbraak richting beneden zal komen
begin hier serieus mijn geduld te verliezen
Agfa, , Deceuninck , euronav, exmar , acacia pharma,fagron,altice europe, nyrstar,transgene, aurora cannabis ,mdxhealt, pharming, , econocom

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 256
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 103
Contact:

Re: Transgene

Berichtdoor And its gone! » 27 Mei 2019 18:45

BRIEF-Transgene Says Results For Primary Endpoint (ORR) Expected In Q4 2019
17:48 (27/05) - Bron: Reuters
May 27 (Reuters) - TRANSGENE SA TRNG.PA :
* LAST PATIENT ENROLLED IN PHASE 2 TRIAL WITH TRANSGENE'S
TG4010
* RESULTS FOR THE PRIMARY ENDPOINT (ORR) EXPECTED IN Q4 2019
* LAST PATIENT ENROLLED IN PHASE 2 TRIAL WITH TRANSGENE'S
TG4010 +
NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED
LUNG CANCER (NSCLC)
* TRIAL HAS ENROLLED PATIENTS WHOSE TUMOR EXPRESSES LOW OR
UNDETECTABLE LEVELS OF PD-L1
* CLINICAL TRIAL IN COLLABORATION WITH BRISTOL-MYERS SQUIBB

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 256
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 103
Contact:

Re: Transgene

Berichtdoor And its gone! » 27 Mei 2019 19:13

Gevonden op Boursorama

Sillajen, CHA Hospital to co-develop immunotherapy
By Lee Han-sooPublished 2019.05.22 18:26Updated 2019.05.22 18:26comments 0글씨키우기글씨줄이기Send MailPrint페이스북트위터구글카카오스토리
Sillajen said Wednesday it has entered an agreement with CHA Bundang Hospital to co-develop an immunotherapy combination treatment.


Sillajen vice president Song Myung-seok (right) and CHA Bundang Hospital CEO and President Kim Jae-hwa signed a cooperative agreement, at CHA Bundang Hospital in Seongnam, Gyeonggi Province, Wednesday.
Under the accord, the two sides will conduct a phase 2 clinical trial to confirm the objective response rate for Pexa-vec and Opdivo as a combination therapy, for 60 patients with colorectal cancer, stomach cancer, cholangiocarcinoma, pancreas cancer or other solid tumors.

Previous researches have shown that Pexa-vec can overcome immunity of conventional immunotherapy by inducing immune cell infiltration in the tumor microenvironment, which is why the company expects a synergistic effect with an anticancer drug, Shillajen said.

By expanding the combination therapy to Pexa-vec and immunotherapeutic agents, the company plans to strengthen its competitiveness in the therapeutic market by laying the foundation for new treatment options.

“We will expand the cooperation based on the strength of CHA Bundang Hospital’s initial clinical trial execution platform and basic medicinal research capacity, and develop the combination treatment into a best in class drug,” Sillajen Vice President Song Myung-seok said.

corea022@docdocdoc.co.kr


Marbull liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 256
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 103
Contact:

Re: Transgene

Berichtdoor And its gone! » 05 Jun 2019 18:56

June 5, 2019 - Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
Peer-reviewed publications confirm the potential
of Transgene’s TG4001 and TG6002
• Therapeutic vaccine TG4001, administered as a single agent, demonstrated statistically significant
curative activity at 30 months in randomized Phase 2b trial in HPV-associated CIN 2/3
• Oncolytic virus TG6002 shows increased tumor selectivity and strong antitumor activity in
several preclinical models
Strasbourg, France, June 5, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company
that designs and develops virus-based immunotherapies for the treatment of solid tumors, announces
the publication of two articles highlighting the potential of TG4001 and TG6002, two clinical-stage
products, that are expected to generate new clinical data in H2 2019
.
TG4001 in Gynecologic Oncology
The data confirm the potential of TG4001 (Tipapkinogen Sovacivec), administered as a monotherapy, to
treat precancerous HPV-induced lesions (cervical intraepithelial neoplasia - CIN2/3).
These clinical results, with a 30-month follow up, are highly supportive of the ongoing development
of TG4001 in combination with avelumab in HPV-positive cancers, including head and neck carcinomas
(NCT03260023), for which efficacy data are expected in H2 2019.
• Of the 129 women randomized to TG4001 and 63 to placebo, complete resolution 1 was
significantly higher in the vaccine group than placebo for CIN 2/3 regardless of the 13 high-risk
HPV types assayed (24% vs. 10%, p < 0.05).
• Irrespective of baseline HPV infection, viral DNA clearance2 was higher in the vaccine group
compared to placebo (p < 0.01).
• TG4001 was well tolerated with the most common adverse events being injection site reactions.
Ref: The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical
intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of followup, D.M. Harper, et al., Gynecologic Oncology - https://doi.org/10.1016/j.ygyno.2019.03.250
TG6002 in Molecular Therapy Oncolytics
Transgene provides detailed preclinical data on its oncolytic virus TG6002. Based on an optimized
Copenhagen strain of vaccinia virus, TG6002 displays a proprietary double gene deletion (TK-RR-) and a
patented FCU1 gene, that allows the production of chemotherapy (5-FU) directly in the tumor.
TG6002 is currently being evaluated in a Phase 1/2 study patients with colorectal cancer (NCT03724071).
• TG6002 has an improved safety and efficacy profile and has shown to selectively replicate in
tumor cells.
• Several models highlight the promising activity of the oncolytic virus, particularly in colorectal
carcinoma models.
Ref: The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two
Genes Involved in Nucleotide Metabolism, J. Foloppe, et al., Molecular Therapy Oncolytics -
https://doi.org/10.1016/j.omto.2019.03.005


BRIEF-Transgene Oncolytic Announces Potential Of TG4001 And TG6002
17:56 (05/06) - Bron: Reuters
June 5 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE: PEER-REVIEWED PUBLICATIONS CONFIRM THE
POTENTIAL OF
TRANSGENE’S TG4001 AND TG6002
* ONCOLYTIC VIRUS TG6002 SHOWS INCREASED TUMOR SELECTIVITY
AND
STRONG ANTITUMOR ACTIVITY IN SEVERAL PRECLINICAL MODELS
* THERAPEUTIC VACCINE TG4001, ADMINISTERED AS A SINGLE
AGENT,
DEMONSTRATED STATISTICALLY SIGNIFICANT CURATIVE ACTIVITY AT 30
MONTHS IN RANDOMIZED PHASE 2B TRIAL IN HPV-ASSOCIATED CIN 2/3
* CLINICAL RESULTS ARE HIGHLY SUPPORTIVE OF ONGOING
DEVELOPMENT OF
TG4001 IN COMBINATION WITH AVELUMAB IN HPV-POSITIVE CANCERS
* TG4001 WAS WELL TOLERATED WITH MOST COMMON ADVERSE EVENTS
BEING
INJECTION SITE REACTIONS

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))


verwacht dat we zeker iets over de 3€ gaan morgen :lol:


Word gratis lid op Beursig.com

Discussieer met duizenden beleggers, profiteer van minder advertenties, ideaal voor smartphone, betere gebruikservaring en abonneer op uw favoriete onderwerpen.

Registreer nu binnen enkele tellen